Open in interactive viewer → charts, metric popovers & call review

SIGA's Preparedness Story Waits for Washington — Again

A Canadian contract, a $116 million cash pile, and a PEP filing that just slipped to 2028.
SIGA · Earnings Call · 2026-11-09

A Quarter Defined by Absence

SIGA's third quarter was the kind of quarter its business model almost guarantees: no product revenue. “For the third quarter, there are no product sales to customers.” — Dan Luckshire · 2026-11-09 That is not a surprise — management has spent years warning investors that government procurement arrives in lumps — but it still leaves the P&L looking empty. Nine-month product revenue was roughly $42 million, most of it booked in the second quarter, while the third quarter produced a $3 million net loss and a $7 million pre-tax operating loss. The balance sheet remains the ballast: $116 million of cash and no debt, against a $234 million market cap. The stock is down 13% over the last 90 days and remains 87.5% below its 2022 peak, so the market is not paying for the story — it is paying for the cash and an option on the next U.S. contract. $118 million of effective net cash is the reason this remains a waiting game rather than a financing story. Revenue itself is not in a smooth decline; it is skipping quarters, the signature of lumpy government buying. $41 million in the latest reported quarter was mostly a prior-period delivery, not a run-rate.

The U.S. Contract That Isn't

The central missing item is still the new U.S. government contract. In August, CEO Diem Nguyen was direct about the delay: “this process has certainly taken longer than generally expected” — Diem Nguyen, Chief Executive Officer · 2026-08-06, citing the scale of change inside HHS, the transition from BARDA to SNS, and open leadership positions. At that time, management was still pointing toward a new contract and an order against it, with a delivery targeted by March of the next year. Three months later, the language has shifted from timing to principle.

At the same time, a compelling case for preparedness does not always translate into predictable procurement. ... the timing of an award remains uncertain.

Diem Nguyen · 2026-11-09
That is the tension of this call. The company's top new keyword is smallpox preparedness, followed closely by the case for preparedness. Both are true. Both are also what you say when you cannot say when the order lands. The analyst asked whether the U.S. midterms change biodefense funding or the RFP trajectory; Nguyen argued that biodefense has historically enjoyed bipartisan support and is not a large or controversial budget line, and that the election should not materially change the process beyond a normal transition period. That is a reasonable answer, but it is not a catalyst. The stock needs a signature, not a sentiment.

Canada Is Real, But It Is Not the SNS

The freshest concrete news is Canada. SIGA signed a contract with Canada's Department of National Defence worth up to roughly $15 million over five years — about $9 million in firm orders over the first three years and up to $6 million in options at Canada's discretion. This is the second TPOXX contract with the Canadian military, and it is the international opportunity management had flagged last quarter. Dan Luckshire confirmed that deliveries are expected to start in 2027, with equal annual courses across the first three fiscal years. There is also another international contract in late-stage negotiations. That is genuine diversification, and the Canadian Military is exactly the kind of customer that should stockpile antivirals alongside vaccines. But scale matters: $9 million of firm orders over three years is small against the $26 million of IV TPOXX delivered to the U.S. Strategic National Stockpile in the first nine months of 2026, let alone the old BARDA contract. Canada is a proof point, not a replacement.

The Delay Buried in Development

The more consequential news was tucked into the development update: the post-exposure prophylaxis supplemental NDA is now expected in 2028. “we now expect to file our supplemental NDA in 2028” — Diem Nguyen · 2026-11-09 is a two-year slip from the prior target. In May 2025, management was “targeting a submission in the first half of 2026” — Diem Nguyen, Chief Executive Officer · 2025-05-08. The cause is not a failed study but additional FDA-requested validation and laboratory work around the CDC's immunogenicity sample analysis. That is a legitimate scientific reason, and the PEP use case — protecting military personnel and first responders after exposure — remains strategically relevant. But investors should not underestimate what a 2028 filing does to the optionality case. It removes a nearer-term label expansion catalyst and pushes the PEP revenue debate into a period when the U.S. contract should already be resolved, one way or another. The pediatric formulation program is still expected to produce Phase I results by year-end, which could extend TPOXX coverage from infants to adults and strengthen the stockpile argument. That is now the more visible near-term development catalyst.

What the Market Is Actually Pricing

SIGA is not expensive on cash and not cheap on hope. The equity trades at about 4.9x trailing revenue, but the revenue base is episodic and the next U.S. order is the swing factor. The balance sheet gives management time to wait, and the absence of any dividend or buyback discussion on this call is itself a signal: after years of special dividends, capital return has fallen off the keyword map while the company preserves flexibility for the procurement gap. That is prudent, but it also means shareholders are being asked to underwrite a binary event with no income support. The stock's long drawdown says they have been doing so for a while. The catalyst path is narrow: a U.S. award, another international order, and pediatric data by year-end. Until one of those lands, SIGA's smallpox preparedness sermon is compelling — and insufficient.